Significance of E-cadherin expression in triple-negative breast cancer
Authors:
Open Access
- 15 June 2010
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 103 (2) , 249-255
Abstract
Triple-negative breast cancer (TNBC), a subtype of breast cancer that is oestrogen receptor (ER) negative, progesterone receptor (PR) negative, and human epidermal growth factor receptor 2 (HER2) negative, has a poor prognosis. Although a correlation between E-cadherin expression level and outcome has been demonstrated among all types of breast cancer, little is known about the significance of E-cadherin expression levels in TNBC. A total of 574 patients who had undergone a resection of a primary breast cancer except for invasive lobular carcinomas were enrolled in this study. Expressions of ER, PR, HER2, and E-cadherin were assessed by immunohistochemistry. We examined the association between TNBC and other clinicopathological variables and evaluated the significance of the E-cadherin expression. Among the 574 breast cancer cases, 123 (21.4%) revealed a triple-negative phenotype. Patients with TNBC experienced more frequent lymph node metastasis (P=0.024) and a poorer prognosis (PPP=0.032). Furthermore, in the 123 TNBC cases, the prognosis of patients with an E-cadherin-negative expression was significantly worse than that of E-cadherin-positive patients (P=0.0265), especially for those in clinical stage II (P=0.002). A multivariate logistic regression analysis showed a reduction of the E-cadherin expression to be an independent prognostic factor (P=0.046). E-cadherin expression may be a useful prognostic marker for classifying subgroups of TNBC.Keywords
This publication has 22 references indexed in Scilit:
- Molecular mechanisms controlling E-cadherin expression in breast cancerBiochemical and Biophysical Research Communications, 2009
- Reduction of E-cadherin expression is associated with non-lobular breast carcinomas of basal-like and triple negative phenotypeJournal of Clinical Pathology, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Prognostic markers in triple‐negative breast cancerCancer, 2006
- Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importanceEuropean Journal of Cancer, 2006
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- DNA hypermethylation in breast cancer and its association with clinicopathological featuresCancer Letters, 2006
- High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysesInternational Journal of Cancer, 2005
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences, 2001